OOIR: Observatory of International Research

Papers

(The TQCC of ESMO Open is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	246
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	244
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	187
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	162
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	159
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	153
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	144
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	141
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	137
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	128
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	124
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	111
Table of Contents	110
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	106
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	101
Table of Contents	98
Table of Contents	96
ESMO	95
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	88
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	87
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	86
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	83
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	80
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	77
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	75

83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	74
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	74
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	74
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	73
43eP Is age a risk factor for locally advanced cervical cancer persistence?	70
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	69
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	68
Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist	68
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	67
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	66
Editorial Board	63
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	63
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	63
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	62
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	61
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	60
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	60
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	59
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	58
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	58
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	56
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	56
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	55
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	54
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	54
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	53
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	53
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	51
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	49
Editorial Board	49
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	48
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	48
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	48
Editorial Board	48
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	47
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	46
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	46
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	44
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	44
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	44
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	43
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	42
Editorial Board	42
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	42
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	41
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	41
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	40
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	39
36P Next-generation sequencing in liquid biopsy for advanced NSCLC: Indian tertiary cancer centre experience	38
58P Peripheral T cell phenotypes as predictors of progression and treatment response in mCRC: A prospective immunoprofiling study	38

Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?	38
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	38
8P Unveiling functional reprogramming in pancreatic cancer: An integrative transcriptomic and explainable machine learning approach	38
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	37
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	37
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	37
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	37
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	37
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	36
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	36
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	35
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	35
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	35
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	35
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	35
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	34
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	34
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	34
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	34
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	34
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	33
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	33
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	33
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	33
OP2-6 Favorable outcomes of EBV-associated gastric cancer treated with first-line immunotherapy plus chemotherapy: A multicenter real-world study	33
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	32
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	32
16P Dacomitinib in advanced NSCLC patients with uncommon EGFR mutations: A multicenter, single-arm, phase II study and biomarker analysis (DANCE study)	32
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)	32
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	32
547P From hospital to home: Pilot experience of home-based cancer immunotherapy delivery in an area of Bizkaia, Basque country	32
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	32
PP278 Role of cancer stem cells and inflammatory markers in the diagnosis and progression of prostate cancer	32
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer	32
465P An alternative strategy for lung cancer treatment: Targeting mTORC2	31
17P Acquired BRAF V600E as bypass resistance to EGFR TKIs in EGFR-mutant NSCLC: A global multicenter cohort study	31
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	31
491P Tumor treating fields (TTFields) augment antitumor and immune activity of immunochemotherapy in preclinical models of non-small cell lung cancer	31
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	30
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	30
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	30
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	30
166P Hemin overcomes cetuximab resistance in colorectal cancer through ferroptosis	29
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	29
37P Fix the data, not the model: LMIC challenges in AI for precision oncology	29
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	29
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	28
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	28
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	28
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	28
12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation	28
442P Sacituzumab govitecan (SG) in patients (pts) with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) within routine clinical practice in Spain: R	27
503P Efficacy and safety of the combination of trastuzumab (T), tucatinib (TUC), and oral vinorelbine (VNR) in patients (pts) with HER2+ metastatic breast cancer (MBC): Results from the TrasTUCAN (GEI	27
447P HER3 expression and overall survival (OS) in ICARUS-BREAST01: A phase II study with patritumab deruxtecan (HER3-DXd) patients (pts) with HR+/HER2- advanced breast cancer (ABC)	26
150eP High robustness and reproducibility of the genomic signature EndoPredict through quality control programs in France since 2017	26
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	26
526P An exploratory analysis of the relationship between oncotype score and the duration of response to first-line CDK4/6 inhibitors: Could we add this to our prognostication toolbox for metastatic br	26
317TiP POP-ELA: a short-term preoperative, phase II, window-of-opportunity study, evaluating activity and safety of Elacestrant with and without ovarian function suppression (OFS) in premenopausal pat	26
280P Omitting chemotherapy (CT) in pN2-3, luminal A-like early breast cancer (eBC)	26
682P Implementation of a geriatric oncology care pathway for older patients with breast cancer in a regional public hospital in Portugal	26
130eP Programmed death-ligand 1 (PD-L1) immunohistochemical expression in triple-negative breast cancer: A clinicopathological study from a tertiary care center in South India	26
623P Patient navigation integrated into multidisciplinary breast cancer care: A prospective patient-reported evaluation from an LMIC center	26
88P A phase Ib/II study of adebrelimab plus capecitabine and oxaliplatin in patients with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer	25
E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study	25
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	25
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	25
193P A comprehensive analysis of the role of ADCY7 in cervical cancer: Carcinogenesis, expression patterns, and prognostic significance	25
90P Camrelizumab, paclitaxel and nedaplatin as conversion therapy for locally advanced /advanced esophageal squamous cell carcinoma: A phase II, single-arm study	25
36P Preliminary results of bulumtatug fuvedotin (BFv, 9MW2821) in combined with toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a phase Ib/II clinical study	25
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	25
158eP Molecular regulation of pyroptosis by cisplatin via pyrin pathway in bladder cancer	25
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	25
170TiP MAIA-ovarian (NCT06888921) adaptive platform clinical trial to evaluate safety and efficacy of COM701 maintenance treatment in relapsed platinum-sensitive ovarian cancer (PSOC)	25
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-re	25
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	24
Hope and despair in cancer and other illnesses: a clinical framework for adaptive hope across the illness trajectory	24
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	24
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	24
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	24
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	24

Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study	24
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	24
11MO First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a phase II trial in patients (pts) with non-small cell lung cancer (NSCLC)	24
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	24
Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies	24
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	23
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	23
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	23
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	23
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	23
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	23
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	22
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	22
481P Trends in mortality due to malignant and benign breast neoplasms in the United States from 2018 to 2023: A CDC wonder analysis	22
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	22
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	22
273P Clinicopathological features and outcomes in patients with BRCA-associated HR+/HER2- breast cancers eligible for adjuvant CDK4/6 and PARP inhibitors	22
439P The bio-psycho-social predictors of mental health among women with breast cancer	22
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	22
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	22
283P Incidence of male breast cancer in genetically high-risk patients	22
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	22
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	22
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	21
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	21
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	21
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	21
487P Health care provider’s adherence to clinical practice guidelines in diagnosing and staging breast cancer: An observational study	21
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	21
220P Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study	21
178P Comparative study between wise pattern and non-vertical scar reduction mammoplasty	21
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	21
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	21
134P Gene alterations in Mongolian breast cancer patients	21
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	21
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	20
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	20
154P Alternative splicing in non-small cell lung cancer evolution	20
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	20
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	20
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	20
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	20
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	20
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	20
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	20
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	20
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	20
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	20
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	20
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	20
65eP Real-world impact of pembrolizumab plus lenvatinib in metastatic uveal melanoma: A retrospective multicenter study	19
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	19
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	19
Molecular immune signature identifies microglia and NK cell infiltration as a favorable prognostic marker in adult-type high-grade glioma	19
34P DREAM: Data-driven drug repositioning through integrative analysis and machine learning	19
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	19
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	19
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	19
131P Mortality and economic burden associated with late-stage diagnosis of breast cancer	19
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	19
Editorial Board	19
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	19
191eTiP The Syrian TELE-TAT trial: A pragmatic, randomized study of tele-oncology for proactive adverse event management in patients receiving oral targeted therapies in a conflict zone	19
62MO Engineering CAR-NK cells with enhanced persistence and functionality for cancer immunotherapy	19
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma	19
220eTiP A first-in-human, phase I study of XB010, a 5T4-MMAE ADC, in patients with non-small cell lung cancer (NSCLC) and other solid tumors	18
385P “Breathe to Live”: A lung cancer advocacy and community awareness campaign in Piwoyi, Abuja, Nigeria	18
17eP Fitzpatrick-guided AI system for ABCD-based dermoscopic analysis and melanoma risk stratification	18
189eP Prognostic value of CT-derived skeletal muscle quality in advanced NSCLC treated with immunotherapy-based regimens	18
305P Role of the pan-immune-inflammatory value in stage III NSCLC treated with chemoradiotherapy with or without durvalumab	18
208eP Triple-targeted therapy with encorafenib, binimetinib and osimertinib in BRAF- and EGFR-co-mutated non-small cell lung cancer: A single-center experience	18
512P Molecular landscape of BRCA-mutated NSCLC	18
MAP 2025 Officers and Organisation	18
45P Phenotypic diversity of lynch syndrome and the role of NGS in its molecular characterization	18
284P Clinical validation of CCR2-targeted SPECT imaging as a biomarker for monocyte-macrophage infiltration and prognosis in non-small cell lung cancer	18
130P Randomized study of dexamethasone (DEX) administration methods for advanced lung cancer patients with anorexia (NJLCG1602/NEJ031)	18
425P Final analysis of the phase Ib-II trial of dendritic cell vaccination plus atezolizumab in ES-SCLC (VENEZOLUNG)	18
105P Interim data on first-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) from the Germ	18
70eP Decoding ambiguity of variants of uncertain significance (VUS) of non-small cell lung carcinoma (NSCLC) using a comprehensive NGS panel: Landmark study from an Indian cohort	18
87P First-line treatment patterns in metastatic NSCLC patients in Brazil: A real-world analysis by PD-L1 status	18
532eP Co-mutation and compound mutation landscape in Indian lung carcinoma: A real-world NGS study of 118 patients	18
18P Characterization and management of sevabertinib-induced diarrhea in the SOHO-01 study	18
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	17
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	17
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	17
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	17
57P Multi-matrix untargeted metabolomics profiling reveals potential non-invasive prognostic and predictive biomarkers in metastatic colorectal cancer: The CRC-Tsen study	17
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	17
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	17
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	17
74P Evaluation of the clinical significance of rare epidermal growth factor receptor exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small cell lung cancer: A five-yea	17
124P Melittin inhibits the growth of hepatocellular carcinoma Huh7 cells by downregulating LARS2 and ZNF19	17
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	17
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	17
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	17